ALLEGRA MEDICAL TECHNOLOGIES LIMITED SYDNEY 20 APRIL, 2016 -Allegra Orthopaedics Limited (Allegra) (ASX: AMT), advises that it has appointed Jenny Swain as its Chief Executive Officer with effect from 2 May 2016.
The appointment follows a strategy review based on the decision to place a greater emphasis on sales and marketing by outsourcing Allegra's manufacturing activities.
The appointment was based on a recommendation from Chris Calamos who will step down from his role as Chief Executive Officer and Chief Financial Officer. Importantly, Chris will continue to provide consulting services to Allegra supporting management and also taking the lead on a number of strategic initiatives including the commercialisation of a synthetic bone substitute. .
Jenny Swain joined Allegra in February 2011 as National Sales Manager having spent 10 years in a similar role with LifeHealthcare driving the growth of its Orthopaedic sales division.
Allegra's Executive Chairman, Peter Kazacos, said: "Having a background in operating theatres Jenny has developed strong relationships with surgeons not only in Australia but also internationally so that she is well placed to lead Allegra's sales expansion".
Jenny Swain said: "This is a great opportunity. I am looking forward to growing the Allegra business through our renewed focus on our existing products, as well as sourcing new products to introduce to the market under the Allegra brand.
Rob Truscott will perform the role of Chief Financial Officer. Robert joined Allegra in early November 2015 and is a highly experienced professional with over 25 years' experience in senior finance roles. After qualifying, Rob spent six years working in London before returning to Sydney to further his career in operationally focused finance roles. Rob is a qualified CPA and holds a Bachelor of Commerce degree from University of Western Sydney (UWS).
Contact Details:
Peter Kazacos - Executive Chairman Allegra Orthopaedics
T: 02 9119 9200
Allegra's mission is to deliver to its customers the highest quality medical products in conjunction with unparalleled customer support.
Allegra's principal product is the Active Total Knee, which has significantly improved the quality of life for people globally.
Allegra is also the global licensee to a composite biocompatible ceramic material known as Sr-HT- Gahnite from the University of Sydney for veterinary and orthopaedic solutions. The Sr-HT-Gahnite is still under development and preliminary studies have duplicated the mechanical strength of the bone. Preclinical studies currently being performed indicate good bioactivity and ingrowth of bone into the synthetic scaffold prepared from the ceramic material. Importantly, it is 100 times mechanically stronger than synthetic bone substitute materials in clinical use.
The company continues to build upon its extensive portfolio of patents. It has extensive research relationships with universities, companies and surgeon inventors. Our partnerships are creating innovative products which will deliver significant shareholder value.
The company continues to build upon its extensive patent and product development portfolio. We have extensive research relationships with universities, companies and surgeon inventors. Our partnerships are building innovative products which will deliver significant shareholder wealth.
Allegra Orthopaedics Limited issued this content on 20 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 21 April 2016 09:52:11 UTC
Original Document: http://www.allegraorthopaedics.com/content/uploads/2016/04/ASX160420MgtChanges.pdf
